View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...
MedPage Today on MSN
Complement inhibitor slowed kidney decline in IgA nephropathy
Continued FDA approval of iptacopan was contingent on 2-year trial data ...
According to TipRanks.com, Skor is a 4-star analyst with an average return of 15.8% and a 61.2% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, ...
Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.
Dan Yoo took a breath before describing what he saw when he stopped into work on a Sunday morning at the Larry C. Hardy ...
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...
Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported fourth-quarter profit of $2.7 million. The San Diego-based company said it had net income of 3 cents per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results